Comparative Pharmacology
Head-to-head clinical analysis: TRUPHYLLINE versus VOSPIRE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRUPHYLLINE versus VOSPIRE ER.
TRUPHYLLINE vs VOSPIRE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Truphylline is a xanthine derivative that inhibits phosphodiesterase (PDE) and blocks adenosine receptors, leading to bronchodilation, increased respiratory drive, and anti-inflammatory effects.
Vospire ER (albuterol sulfate) is a beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via activation of adenylyl cyclase, leading to bronchodilation.
Aminophylline 5-6 mg/kg IV loading dose over 20-30 minutes, then 0.5-0.7 mg/kg/h continuous IV infusion; theophylline 300-600 mg PO daily divided q6-12h, titrated to serum theophylline level of 5-15 mcg/mL.
Oral: 30-60 mg once daily in the morning, with or without food. Maximum dose: 60 mg/day.
None Documented
None Documented
Terminal half-life: adults 6-8 hours, children 3-5 hours, neonates 24+ hours. Prolonged in hepatic or cardiac impairment.
Terminal elimination half-life of vospire ER is approximately 12-15 hours. This prolonged half-life supports once-daily dosing and provides sustained bronchodilation over the dosing interval.
Renal excretion of unchanged drug (80-90%) and metabolites; biliary/fecal elimination <10%.
Primarily renal (approximately 75% as unchanged drug and metabolites) and biliary/fecal (approximately 25%).
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator